Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947775 | 0.88 | LMNA (0.50) | PRKDCMAPTSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL1252295 | 0.79 | CHRM2 (0.57) | PRKDCMAPTSMN1; SMN2LMNAAKR1C3 | |
| SCHEMBL24236054 | 0.79 | PRKDC (0.54) | PRKDCMAPTSMN1; SMN2LMNAAKR1C3 | |
| SCHEMBL159947 | 0.79 | LMNA (0.42) | MAPTSMN1; SMN2LMNAAKR1C3MAPK1 | |
| SCHEMBL161110 | 0.79 | LMNA (0.42) | PRKDCMAPTSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL27847540 | 0.79 | LGMN (0.46) | MAPTSMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL1570342 | 0.76 | KMO (0.48) | PRKDCMAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27943380 | 0.76 | CNR2 (0.50) | MAPTSMN1; SMN2LMNAAKR1C3ALDH1A1 | |
| SCHEMBL1653981 | 0.75 | AKR1C3 (0.47) | MAPTSMN1; SMN2LMNAAKR1C3ALDH1A1 | |
| SCHEMBL27953793 | 0.75 | CNR2 (0.52) | MAPTSMN1; SMN2LMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-110770227-B | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| CN-110536892-B | Novel bicyclic pyrazole derivatives | 拜耳动物保健有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-109311813-B | Palladium-catalyzed meta-C-H functionalized universal ligands | 斯克利普斯研究院 | 2023-02-28 | — | — | CN | disclosed |
| EP-4132911-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667221-A | Substituted fused oxazines as insect repellent compounds | 拜耳动物保健有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109890793-B | Novel anthelmintic quinoline-3-carboxamide derivatives | 拜耳动物保健有限责任公司 | 2022-11-18 | — | — | CN | disclosed |
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-11130768-B2 | Bicyclic pyrazole derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3615527-A1 | NEW AZAQUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110770227-A | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3538512-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019002132-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018197401-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
| CN-102625799-A | Heterocyclic compounds and their uses | AMGEN INC | 2012-08-01 | — | — | CN | disclosed |
| CN-102227409-A | Pyridine-3-carboxyamide derivative | KOWA CO | 2011-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | RECQL, H1-5, CHRM1 | PRKDC 4523/4885MAPT 4413/4885SMN1; SMN2 1992/4885 |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | CYP1B1, QPCT, CYP4B1 | PRKDC 4182/4885MAPT 4074/4885SMN1; SMN2 4150/4885 |
| US-11485733-B2 | Azaquinoline derivatives | RECQL, H1-5, H1-3 | PRKDC 4528/4885MAPT 4349/4885SMN1; SMN2 1929/4885 |
| US-11130768-B2 | Bicyclic pyrazole derivatives | CYP1B1, CYP3A43, CYP3A5 | PRKDC 4200/4885MAPT 4008/4885SMN1; SMN2 3917/4885 |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | PRKDC 4884/4885MAPT 4232/4885SMN1; SMN2 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.